Founder & Chief Executive Officer

Drug Hunter on LinkedIn: MYT1, Pan-RAF, Pan-RAS and More: Dec. '23 Compound Collection |…

Drug Hunter on LinkedIn: 2023 Novel Large Molecule FDA Drug Approvals

Vertex Pharmaceuticals's NaV1.8 inhibitor for Ph. III pain | Drug Hunter posted on the topic

Drug Hunter on LinkedIn: Targeting Post-Transcriptional RNA-Modification with a First-to-Clinic…

Principal Research Analyst, Targets & Mechanisms of Action

Drug Hunter™ is an essential knowledge platform for industry R&D innovators turning molecules into medicines. The Research Analyst- Targets and Mechanisms of Action will play a crucial role in expanding the current Drug Hunter content by creating biology-focused reviews on emerging and exciting targets and novel mechanisms for drugging those targets.

Sign up with Google

Sign in with Google